STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL. Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Thursday, November 30, 2023, at 10:50 a.m. ET.
A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.
GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation, fueled by one of the world’s largest, rare disease data sets. For more information, please visit www.genedx.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
GeneDx Investor Relations Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
GeneDx Media Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$127.92 |
| Daily Change: | 5.23 4.26 |
| Daily Volume: | 110,184 |
| Market Cap: | US$3.680B |
October 09, 2025 October 08, 2025 October 01, 2025 September 18, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
